Novel therapeutic modalities such as bispecific antibodies (BsAbs) that simultaneously target two antigens are demonstrating promising clinical results in oncology with benefits that include enhanced specificity, reduced side effects, and increased efficacy. Despite the challenges in developing BsAbs, progress in protein/antibody engineering has resulted in an increase in BsAbs and their preclinical assessment.
Watch today to gain invaluable insights on the development of BsAbs from our industry experts.
Rajendra Kumari, PhD, Executive Director, Integrated Solutions, Crown Bioscience
As Executive Director of Integrated Solutions within the Commercial and Strategic Development team, Rajendra leads the focus of cross-disciplinary solutions for drug discovery and development. She has over 20 years of oncology research experience with a Ph.D. in Molecular Pharmacology from the University of Leicester (UK). Prior to joining Crown Bioscience, Rajendra held post doctoral fellowships and Assistant Professor position in the Division of Preclinical Oncology within the Medical School, University of Nottingham where she developed in vitro and in vivo preclinical models including patient-derived systems and imaging capabilities. Rajendra also co-founded PRECOS Ltd in 2010, serving as COO and then following merger with Crown Bioscience, as CSO and General Manager for Crown Bioscience UK. In 2018, Rajendra became Global Head of Scientific Communications for all platforms at Crown Bioscience Inc., working closely with multiple divisions and global departments to support the commercialization of R&D activity and capabilities. Rajendra is a member of the AACR and BACR and has authored over 40 abstracts and publications.
Henry Li, PhD, Chief Executive Officer and Chief Scientific Officer, HanX Biopharmaceuticals
Dr. Li is responsible for the overall strategy and development for HanX Biopharmaceuticals. He leads the efforts to build the company’s new drug pipelines as well as supporting the advancement of these pipelines into the clinic, which include two candidate drugs in phase II clinical trials and several candidates in the preclinical stages toward IND filing. Prior to HanX Biopharmaceuticals, Dr. Li was the Chief Scientific Officer of Crown Bioscience. He led the scientific research team of Crown Bioscience for over 10 years and was responsible for the company’s research and innovation, building translational oncology platforms and capabilities to support global cancer drug discovery and development. During this period, Dr. Li led the establishment of the world’s largest commercial patient-derived disease cancer model libraries and other disease models. Before Crown Bioscience, Dr. Li had many years of biopharmaceutical, academic, and R&D experiences in the fields of cancer and viral infection, including leadership roles in several biotech companies. Dr. Li earned his Ph.D. in Molecular Biology/Biochemistry from the University of California Irvine, and completed his postdoctoral training at UCLA School of Medicine. He has published ~90 manuscripts and edited 3 books in the biopharmaceutical field.